摘要
越来越多的证据表明氧化应激是阿尔茨海默病(AD)的发病机理之一。主要的内源性抗氧化剂谷胱甘肽(GSH)已被证明随年龄和包括阿尔茨海默病在内的一些老年性退行性疾病发生而降低。通过调控谷胱甘肽、限制用于合成谷胱甘肽的氨基酸的低毒形式、调控半胱氨酸等方法,从而达到潜在选择补充谷胱甘肽水平以治疗以上病症的治疗目标。然而由于血浆和胞液之间不利的浓度梯度,谷胱甘肽的被动吸收是有限的。同样,一些体内和体外研究证实半胱氨酸高活性化合物对于评估减少的谷胱甘肽水平的疗效有限。研究证明阿尔茨海默病患者体内谷胱甘肽水平的下降可能与谷胱甘肽的体内平衡下调有关,而非底物限制。细胞谷胱甘肽体内平衡取决于谷氨酸半胱氨酸连接酶(GCL)中谷胱甘肽的非变构反馈抑制,这种连接酶负责合成谷胱甘肽的前体γ-谷氨酰半胱氨酸(GGC)。在谷胱甘肽体内平衡可监控的情况下,GGC作为谷胱甘肽合成酶的一种crucialrate受限基质,是负责与GGC凝结甘氨酸形成最终的硫醇三肽、谷胱甘肽的主要酶。在本文中,我们关注GGC在提升细胞谷胱甘肽水平中的治疗潜能。并且讨论GGC高活性化合物被未调节的GS占用并转化为谷胱甘肽和对谷胱甘肽化合物修改的监管的效力,如阿尔茨海默病患者体内谷胱甘肽酯可能克服阻止谷胱甘肽上调的浓度梯度。
关键词: 阿尔茨海默氏病;抗氧化剂;痴呆;谷胱甘肽;氧化应激
Current Alzheimer Research
Title:Therapeutic Approaches to Modulating Glutathione Levels as a Pharmacological Strategy in Alzheimer`s Disease
Volume: 12 Issue: 4
Author(s): Nady Braidy, Martin Zarka, Jeffrey Welch and Wallace Bridge
Affiliation:
关键词: 阿尔茨海默氏病;抗氧化剂;痴呆;谷胱甘肽;氧化应激
摘要: Accumulating evidence has suggested the involvement of oxidative stress in the pathogenesis of Alzheimer’s disease (AD). The main endogenous antioxidant, glutathione (GSH), has been shown to decline with ageing and in several age-related degenerative diseases, including AD. Potential options for replenishing GSH levels as a therapeutic target to treat these conditions include the administration of GSH itself, and low toxicity forms of the limiting amino acid for GSH synthesis; cysteine. However, passive GSH uptake is limited due to an unfavourable concentration gradient between the plasma and cytosol. Similarly, cysteine prodrugs have demonstrated limited efficacy to elevate depleted GSH levels in several in vivo and in vitro models of disease. It has been suggested that the decline in GSH levels in AD, may be associated with down regulation of GSH homeostasis rather than substrate limitation. Cellular GSH homeostasis is regulated by non-allosteric feedback inhibition exerted by GSH on glutamate cysteine ligase (GCL), which is responsible for the synthesis of the GSH precursor γ-glutamylcysteine (GGC). In conditions involving down regulated GSH homeostasis, GGC serves as a crucialrate-limiting substrate for GSH synthetase, the main enzyme responsible for condensing glycine with GGC to form the final thiol tripeptide, GSH. In this review, we focus on the therapeutic potential of GGC to elevate cellular GSH levels. We also discuss the efficacy of GGC prodrugs which would be taken up and converted by the unregulated GS to GSH, and the administration of modified GSH compounds, such as GSH esters that could potentially overcome the concentration gradient that prohibits passive GSH uptake, in AD.
Export Options
About this article
Cite this article as:
Nady Braidy, Martin Zarka, Jeffrey Welch and Wallace Bridge , Therapeutic Approaches to Modulating Glutathione Levels as a Pharmacological Strategy in Alzheimer`s Disease, Current Alzheimer Research 2015; 12 (4) . https://dx.doi.org/10.2174/1567205012666150302160308
DOI https://dx.doi.org/10.2174/1567205012666150302160308 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects
Current Pharmaceutical Design Unmasking the Many Faces of Giloy (<i>Tinospora cordifolia</i> L.): A Fresh Look on its Phytochemical and Medicinal Properties
Current Pharmaceutical Design Coupling of Conjugating Enzymes and Efflux Transporters: Impact on Bioavailability and Drug Interactions
Current Drug Metabolism Recent Patents on Cell Cycle Regulatory Proteins
Recent Patents on Biotechnology Trafficking of Neuronal Two Pore Domain Potassium Channels
Current Neuropharmacology Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry Review of Computer-Aided Models for Predicting Collagen Stability
Current Computer-Aided Drug Design Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry A Novel Fusicoccin Derivative Preferentially Targets Hypoxic Tumor Cells and Inhibits Tumor Growth in Xenografts
Anti-Cancer Agents in Medicinal Chemistry The Hypothalamic-Neurohypophyseal System: Current and Future Treatment of Vasopressin and Oxytocyn Related Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Prolyl Peptidases Related to Dipeptidyl Peptidase IV: Potential of Specific Inhibitors in Drug Discovery.
Current Topics in Medicinal Chemistry Inorganic Nanomedicines and their Labeling for Biological Imaging
Current Topics in Medicinal Chemistry Signaling Pathways Modulating Dependence of Lung Cancer on Mutant Epidermal Growth Factor Receptor and Mechanisms of Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors
Current Pharmaceutical Design Clinical Use of Therapies Targeting Tumor Vasculature and Stroma
Current Cancer Drug Targets Sunlight Vitamin D and Skin Cancer
Anti-Cancer Agents in Medicinal Chemistry Vinorelbine in Cancer Therapy
Current Drug Targets Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target
Current Cancer Therapy Reviews Meet Our Editorial Board Member
Current Pharmacogenomics and Personalized Medicine Potential Association Between TLR4 and Chitinase 3-Like 1 (CHI3L1/YKL-40) Signaling on Colonic Epithelial Cells in Inflammatory Bowel Disease and Colitis-Associated Cancer
Current Molecular Medicine